BCT-197 (acumapimod) is an oral p38 MAP kinase inhibitor being developed as first-line acute therapy for acute exacerbations of chronic obstructive pulmonary disease (AECOPD).

An AECOPD is characterised by a sudden worsening in the COPD patient’s symptoms of dyspnoea, cough and sputum production. These episodes typically last for several days and often require hospitalisation of the patients and an increase in medication. The number of acute exacerbations is directly related to mortality.  AECOPDs occur in the natural course of the disease but are commonly triggered by infections and air pollution. Acumapimod aims to address the airway and systemic inflammation that are characteristic drivers of the disease and to reduce the length of hospital stay.

BCT-197 (1).jpg BCT-197_M (1).jpg BCT-197_M (1).jpg


View Acumapimod poster


  1. National Heart, Lung and Blood Institute (accessed in Dec 2017) 
  2. COPD Coalition 
  3. Mannino et al (2002) MMWR Survell Summ 51: p1-6 
  4. Wier et al (2011) AHRQ, HCUP, Statistical Brief #106 p1-11
  5. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016
  6. De Buck et al (2015) Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197. CPT Pharmacometrics Syst. Pharmacol. 4, 691–700

View clinical studies


VIEW BPS-804 VIEW BGS-649VIEW mph-966